There are currently more than ten phase I/II ongoing clinical trials evaluating PSMA-TAT as a single agent in prostate cancer in different settings and with various radiopharmaceuticals (https://clinicaltrials.gov, https://euclinicaltrials.eu). Here, FOLH1 is linked to prostate carcinoma.